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Background: Little is known about post-infectious pulmonary sequelae in countries like
Cambodia where tuberculosis is hyper-endemic and childhood pulmonary infections are highly
frequent. We describe the characteristics of hospitalized Cambodian patients presenting with
community-acquired acute lower respiratory infections (ALRI) on post-infectious pulmonary
sequelae (ALRIPS).
Methods: Between 2007 and 2010, inpatients 15 years with ALRI were prospectively re-
cruited. Clinical, biological, radiological and microbiological data were collected. Chest radio-
graphs were re-interpreted by experts to compare patients with ALRIPS, on previously healthy
lungs (ALRIHL) and active pulmonary tuberculosis (TB). Patients without chest radiograph ab-
normality or with abnormality suggestive as other chronic respiratory diseases were excluded
from this analysis.
Results: Among the 2351 inpatients with community-acquired ALRI, 1800 were eligible: 426
(18%) ALRIPS, 878 (37%) ALRIHL and 496 (21%) TB. ALRIPS patients had less frequent fever than
other ALRI (p < 0.001) and more productive cough than ALRIHL (p < 0.001). Streptococcuseur du Cambodge, Epidemiology and Public Health Unit, 5 Boulevard Monivong e BP 983, Phnom Penh,
: þ855 23 428 561.
.fr (B. Rammaert).
3 Elsevier Ltd. All rights reserved.
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1626 B. Rammaert et al.pneumoniae, Haemophilus influenzae, and Pseudomonas aeruginosa accounted for 83% of AL-
RIPS group positive cultures. H. influenzae and P. aeruginosa were significantly associated with
ALRIPS compared with ALRIHL. Treatment was appropriate in 58% of ALRIPS patients. Finally,
79% of ALRIPS were not recognized by local clinicians. In-hospital mortality was low (1%) but
probably underestimated in the ALRIPS group.
Conclusion: ALRIPS remains often misdiagnosed as TB with inappropriate treatment in low-
income countries. Better-targeted training programs would help reduce the morbidity burden
and financial costs.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
The United Nations Millennium Development Goals aim to
reverse the tuberculosis (TB) epidemic by 2015 [1]. Despite
a clear reduction in TB incidence between 2010 and 2011,
post-TB pulmonary sequelae remain under-recognized in
most countries. The direct link between the number of TB
episodes and lung damage is well documented [2]. In
addition, widespread lung destruction may occur in spite of
effective anti-tuberculous therapy. Subsequent healing
may result in extensive fibrosis, bronchostenosis, pleura
remodeling with loss of pulmonary volume and traction
bronchiectasis [3]. According to the World Health Organi-
zation (WHO), Cambodia was the country with the highest
documented TB prevalence worldwide at 817/100 000
population in 2012 [1]. Other under-treated bacterial in-
fections such as pulmonary abscesses or purulent pleurisies
may also cause pulmonary and/or pleural sequelae. Finally,
bronchiectasis may result from acute lower respiratory in-
fections (ALRI) with both tuberculous and severe non-
tuberculous pathogens, which are highly prevalent in
Cambodian children [4].
Surveillance of ALRI (the SISEA project, Surveillance
and Investigation of Epidemics in South-East Asia) con-
ducted in two Cambodian provincial hospitals found a high
proportion of pulmonary sequelae diagnosed by systematic
chest radiographs [5]. Local clinicians were unaware of
this form of chronic respiratory disease. As such e and in
absence of systematic microbial identification - patients
are denied appropriate antibiotics and usually referred to
a specialized TB ward for a standard 6-months anti-TB
therapy. We undertook this study to describe the clin-
ical, radiological and microbiological characteristics of
patients presenting with ALRI on post-infectious pulmo-
nary sequelae (ALRIPS) included in the project, comparing
them to other types of ALRI; the management of ALRIPS
patients is also discussed.
Methods
Data from patients in this study were prospectively
collected through the community-acquired ALRI surveil-
lance SISEA from April 2007 to July 2010 in two provincial
Cambodian hospitals. This surveillance project focused on
ALRI epidemiology in Cambodia, a Southeast Asian tropical
country. The patient recruitment and assessment method-
ology is described elsewhere [5e8]. SISEA was approved by
the Cambodian National Ethics Committee for HealthResearch (number 024-NECHR). Patients’ informed consent
was obtained prior to any investigation.
Briefly, after including inpatients with lower tract res-
piratory symptoms for less than 14 days and excluding pa-
tients with known immunodeficiency [5e7], hospital
physicians recorded demographic, clinical, and therapeutic
data as well as on-site biological testing results and
outcome. They assigned a final diagnosis to each patient,
including that of lung sequelae superinfection. On admis-
sion, blood, non-induced sputum, throat and naso-
pharyngeal samples were collected for direct examina-
tion, cultures and molecular diagnostic techniques, per-
formed at Institut Pasteur du Cambodge. Procedures for
viral and bacterial assessment have previously been
described [6,7,9e12]. Direct sputum examination for acid-
fast bacilli (AFB) were performed at the hospital labora-
tories for each patient on admission and repeated during
the following two days. In accordance with Cambodia’s
national TB recommendations, culture was not systemati-
cally performed. A single chest radiograph per patient was
performed on admission. Expert pulmonologists blinded to
the patient’s condition re-interpreted chest radiograph and
then reviewed patients’ medical files to assign a final
diagnosis to each included case.
We extracted from the SISEA database adult patients
(aged 15 years and above) with ALRI and abnormal chest
radiograph on admission. We then excluded from analysis
patients with other respiratory diseases such as pulmonary
fibrosis, post-tobacco emphysema, pneumothorax and
thoracic deformation. We thus classified patients into three
groups: ALRIPS, ALRI on presumed previously healthy lung
(ALRIHL), and pulmonary TB. We finally excluded patients
with positive AFB smears and pulmonary sequelae to avoid
confusion in groups’ comparison (Fig. 1).
The ALRIPS groupwas defined as patientswith clinical and
biological signs compatible with ALRI and presenting post-
infectious pulmonary sequelae on chest radiograph on
admission. Post-infectious pulmonary sequelaewere defined
as radiologically-diagnosed lung lesions highly suggestive of
a previous lung infection such as TB, abscesses, purulent
pleurisies or bronchiectasis. Severe sequelae were defined
by at least combination of two features such as retraction,
pleural thickening, fibrosis, bronchiectasis and cavities.
Fig. 2 illustrates severe sequelae. Moderate sequelae were
defined by the above features taken separately.
The ALRIHL group was defined as patients with clinical,
biological and radiological signs compatible with pneumonia,
pleurisy, pleuro-pneumonia or pulmonary abscess and chest
radiograph showing no signs of post-infectious sequelae.
Figure 1 Flow chart of patient’ inclusions for the post-infectious pulmonary sequelae superinfections analysis, SISEA study,
Cambodia, 2007e2010.
Superinfections of lung sequelae 1627As recommended by WHO, pulmonary TB, was
confirmed by bacteriology or diagnosed by a clinician [13].
Smear-positive and smear-negative cases met the WHO
definition [13].Figure 2 Chest radiograph of severe post-infectious pulmo-
nary sequelae in a Cambodian patient with acute lower respi-
ratory infection, SISEA study, Cambodia, 2007e2010.The definitions of clinical conditions, diabetes, renal
impairment, cardiovascular disease and severity were
described elsewhere [6,7]. First-line antibiotherapy was
defined as the antibiotics regimen received during the first
three days of hospitalization.
Statistical analysis
Median and interquartile range (IQR) were calculated for
continuous data. Number and percentages were deter-
mined for categorical data. Characteristics of patients
with ALRIPS were initially compared to those of patients
with ALRIHL and to those of active pulmonary TB cases
using either Chi-square, or non-parametric tests (Krus-
kaleWallis), as appropriate.
To identify clinical risk factors of having a superinfection
on pulmonary sequelae on admission, the following vari-
ables with p values <0.2 were then introduced in backward
stepwise logistic regression analysis: age in 10-year classes,
gender, comorbidities, clinical signs, and severity.
Statistical significance was defined at a 5% threshold
(p < 0.05). Odd ratios (ORs) are shown only for variables
remaining significant within the final model. Analyses were
performed using Stata 12 (Stat Corp., College Station, TX,
USA) software program.
Results
Demographic, clinical, microbiological and
therapeutic characteristics of ALRIPS
Among 2351 patients aged 15 years and above included in
the surveillance project, 1831 cases with abnormal chest
1628 B. Rammaert et al.radiographs matched the ALRI definition (Fig. 1). Among TB
and ALRIPS patients, 20 had sequelae in association with TB
and were excluded from analysis (Fig. 1). A total of 1800
patients were finally eligible: 426 ALRIPS (18%), 878 ALRIHL
(37%) and 496 TB (n Z 21%). Demographic and clinical
characteristics of these patients are summarized in Table 1.
Of the 426 ALRIPS cases, 47 (11%) reported current or
previous tobacco use. More than a half (n Z 264, 62%)
received treatment prior to admission; only 25 (6%) patients
said they had taken antibiotics. While most (n Z 372, 87%)
of the patients had a productive cough on admission, 68
(16%) had hemoptysis. Chest radiographs showed major
sequelae in 367 (86%) patients. Eleven patients (3%) were
severe on admission.
In the three groups, blood cultures and sputum samples
were obtained for 1649 (92%) and 890 (49%) patients,
respectively. The main pathogens identified are presented
in Table 2. In the ALRIPS group, Haemophilus influenzae,
Streptococcus pneumoniae and Pseudomonas aeruginosa
accounted for 91 (83%) of the 109 positive sputum and one
blood culture. Of the 51 H. influenzae strains with antibi-
otic susceptibility testing results, 23 (45%) produced a
penicillinase, but all of those remained susceptible to
amoxicillin-clavulanate. All the isolated strains of S.
pneumoniae were susceptible to amoxicillin. P. aeruginosaTable 1 Demographic, clinical characteristics and univariate a
respiratory infections (ALRI) on pulmonary sequelae (ALRIPS) (ref
active pulmonary tuberculosis (TB), SISEA study, Cambodia, 2007
ALRIPS
n Z 426
n (%)
Demographic
Age in years, median (IQR) 60 (52e70)
Male gender 198 (45.9)
Co-morbidities
At least one co-morbidity 143 (33.6)
Cardiovascular disease 25 (5.9)
Diabetes 42 (9.9)
Liver disease 2 (0.5)
Renal impairment 4 (0.9)
Tobacco use 47 (11.0)
Excessive alcohol consumption 71 (16.7)
Clinical characteristics
Severity 11 (2.6)
Hypoxemia 18 (4.2)
Hemoptysis 68 (16.0)
Cough 423 (99.3)
productive cough 372 (87.3)
Fever 185 (43.4)
Treated prior to admission 264 (62.0)
Outcome
Discharged alive 350 (82.2)
Transferred to another ward 70 (16.4)
Died or was discharged for death at home 6 (1.4)
Length of hospital stay (days) 10 (7e14)
Results are expressed as n (%), otherwise specified. Significant valuespresented no resistance, except to ciprofloxacine in two
(13%) strains. Concurrent virus detection was noted in 15
(3.5%) patients. Four chest radiographs were highly sug-
gestive of aspergilloma but fungal culture of sputum sam-
ples could not be performed.
The first-line antibiotic prescribed in ALRIPS was
penicillin A for 283 (66%) patients, in combination with
aminoglycosides for 47 (11%). Only 33 (8%) patients
received amoxicillin-clavulanate, which was not available
at hospital pharmacies, and 15 (3.5%) ceftriaxone.
Treatment was correctly adapted to subsequently avail-
able antibiotic susceptibility testing results for 198 (61%)
patients, including 58% (30/52) of patients with H. influ-
enzae, 74% (17/23) with S. pneumoniae, none (0/15) with
P. aeruginosa, and 42% (5/12) with Klebsiella pneumo-
niae. The median duration of treatment was seven days
(IQR 5e10 days). The median length of stay at hospital was
ten days (IQR 7e14 days). In total, six (1%) patients died in
hospital; 350 (82%) went home with or without medical
discharge.
According to experts’ review, ALRIPS were recognized by
local clinicians in 108 (25%) patients, while 56 (13%) were
misdiagnosed as TB cases including 29 (52%) who were
transferred to another hospital and 8 (9%) to another ward
(mainly TB ward).nalysis comparing patients aged 15 years with acute lower
erence group), ALRI on previously healthy lungs (ALRIHL) and
e2010.
ALRIHL p TB p
n Z 878 n Z 496
n (%) n (%)
55 (42e66) <0.001 52 (40e65) <0.001
439 (50.0) 0.233 268 (54.0) 0.022
402 (45.8) <0.001 178 (35.9) 0.461
151 (17.2) <0.001 19 (3.8) 0.148
124 (14.1) 0.03 58 (11.7) 0.372
9 (1.0) 0.304 6 (1.2) 0.227
8 (0.9) 0.961 3 (0.6) 0.56
89 (10.10) 0.619 67 (13.5) 0.255
142 (16.2) 0.821 100 (20.1) 0.173
83 (9.4) <0.001 22 (4.4) 0.131
64 (7.3) 0.03 21 (4.2) 0.995
54 (6.1) <0.001 59 (11.9) 0.074
871 (99.2) 0.857 491 (99.0) 0.62
576 (65.6) <0.001 413 (83.3) 0.084
611 (69.6) <0.001 261 (52.6) 0.005
416 (47.4) <0.001 290 (58.5) 0.279
600 (68.3) <0.001 156 (31.5) <0.001
235 (26.8) <0.001 331 (66.7) <0.001
43 (4.9) 0.002 9 (1.8) 0.627
7 (4e11) <0.001 6 (3e9) <0.001
(p < 0.05) are in bold.
Table 2 Microbiological results and univariate analysis comparing patients with acute lower respiratory infections (ALRI) on
pulmonary sequelae (ALRIPS) (reference group), with ALRI on previously healthy lungs (ALRIHL), and with active pulmonary
tuberculosis (TB), SISEA study, Cambodia, 2007e2010.
Pathogens ALRIPS ALRIHL p TB p
n (%) n (%) n (%)
Bacterial cultures of at least one sputum or blood sample n Z 414 n Z 829 n Z 478
H. influenzae 53 (12.8) 45 (5.4) <0.001 21 (4.4) <0.001
S. pneumoniae 23 (5.6) 26 (3.1) 0.039 10 (2.1) 0.006
P. aeruginosa 15 (3.6) 15 (1.8) 0.05 5 (1.0) 0.01
K. pneumoniae 12 (2.9) 29 (3.5) 0.57 5 (1.0) 0.044
S. aureus 5 (1.2) 3 (0.4) 0.087 3 (0.6) 0.28
B. pseudomallei 1 (0.2) 30 (3.6) <0.001 1 (0.2) 0.91
Other Gram negative bacilli 8 (1.9)a 16 (1.9)b 0.99 3 (0.6)c 0.078
Dual bacterial infection 10 (2.4) 15 (1.8) 0.47 3 (0.6) 0.02
Viral RT-PCR n Z 417 n Z 853 n Z 483
Rhinovirus 20 (4.8) 40 (4.7) 0.93 19 (3.9) 0.52
Influenza A or B 8 (1.9) 9 (1.0) 0.20 3 (0.6) 0.07
Respiratory syncytial virus 9 (2.1) 15 (1.8) 0.62 8 (1.7) 0.58
Coronavirus 10 (2.4) 16 (1.9) 0.53 1 (0.2) 0.003
Other viruses 5 (1)d 13 (2)e 0.65 3 (1)f 0.35
Dual viral infection 2 2 0.46 0 NA
NA: not applicable. Significant values are in bold (p < 0.05).
a A. baumannii (n Z 5), E. coli (n Z 2), S. marcescens (n Z 1).
b A. baumannii (n Z 6), E. coli (n Z 9), R. pickettii (n Z 1).
c A. baumannii (n Z 1), E. coli (n Z 1), P. mirabilis (n Z 1).
d Parainfluenzae virus (n Z 3), adenovirus (n Z 1), human metapneumovirus (n Z 1).
e Parainfluenzae virus (n Z 3), adenovirus (n Z 2), human metapneumovirus (n Z 7), bocavirus (n Z 1).
f Parainfluenzae virus (n Z 1), adenovirus (n Z 2).
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Results of univariate analysis are shown in Table 1. In
comparison with ALRIHL and TB, ALRIPS patients were
significantly older, 338 (80%) being aged 50 years and above
(Fig. 3), and had less fever (43.4% [vs. 69.6%; p < 0.001];
[vs.52.6%; p Z 0.005], respectively). They also stayed
significantly longer at hospital than both other groups, even
though they were more frequently alive at discharge.
Bacteria cultures were more often positive in ALRIPS than
in both ALRIHL and TB groups (26.6% [vs. 18.9%; pZ 0.03];Figure 3 Distribution of acute lower respiratory infections
(ALRI) by age group, SISEA study, Cambodia, 2007e2010.[vs. 10.5%; p < 0.001], respectively). H. influenzae, Pseu-
domonas areuginosa and K. pneumoniae were more
frequently isolated in samples from patients with ALRIPS
than from both other groups (Table 2). There was no sig-
nificant difference for virus yield between groups.
Results of the multivariate analysis are presented in
Table 3. Briefly, the ALRIPS group differed from ALRIHL
in terms of: older age (over 50 years); less known car-
diovascular disease and diabetes; less fever; more pro-
ductive cough; more hemoptysis; and less severity on
admission. In comparison with TB patients, patients with
ALRIPS were 40 years and over, had less fever and more
hemoptysis.Discussion
Our findings indicate that clinicians and public health spe-
cialists are little aware of the burden of unrecognized
sequelae in a TB-endemic country. In our study, nearly one
in four adult patients admitted for ALRI presented super-
infection on post-infectious sequelae. These patients were
mostly aged 50 and above. Chronic pulmonary disease was
often very advanced and associated with Gram-negative
bacilli and S. pneumoniae. Although AFB smears remained
negative, these cases of superinfected sequelae were
misdiagnosed and sometimes treated as active TB.
Furthermore, the empiric first-line antibiotic treatment
used was inappropriate according to the antibiotic sus-
ceptibility testing results in nearly one in three cases.
Table 3 Results of multivariate analysis and odds ratios (OR) of acute lower respiratory infection on previously healthy lungs
(ALRIHL) or active pulmonary tuberculosis (TB) groups compared to ALRIPS (reference group), SISEA study, Cambodia,
2007e2010.
Variable ALRIHL TB
OR p CI 95% OR p CI 95%
Male gender e NS e NA
Aged 20e29 years e NS e e NS e
Aged 30e39 years e NS e e NS e
Aged 40e49 years e NS e 1.90 0.013 1.15e3.16
Aged 50e59 years 2.15 <0.001 1.49e3.09 3.52 <0.001 2.21e5.60
Aged 60e69 years 2.45 <0.001 1.72e3.47 4.83 <0.001 3.04e7.69
aged 70e79 years 3.39 <0.001 2.32e4.97 4.69 <0.001 2.91e7.57
Aged  80 years 3.22 0.003 1.50e6.93 5.56 <0.001 2.18e14.18
Cardiovascular disease 0.35 <0.001 0.22e0.56 e NS e
Alcohol abuse NA e NS e
Diabetes 0.55 0.004 0.36e0.82 NA
Severity 0.38 0.005 0.19e0.74 e NS e
Hypoxemia on admission e NS e NA
Fever on admission 0.47 <0.001 0.36e0.61 0.67 0.004 0.51e0.88
Hemoptysis 1.87 0.003 1.23e2.83 1.55 0.031 1.04e2.32
Productive cough 3.16 <0.001 2.26e4.41 e NS e
Treatment prior to admission e NS e NA
OR: odds ratio; CI 95%: confidence interval 95%; NA: not applicable.
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tween active TB, ALRIHL and ALRIPS. Patients in the ALRIPS
group had more productive cough and were less often
febrile than in the other groups. But taken individually,
these symptoms are poor clinical indicators. Hemoptysis
was more prevalent in the ALRIPS group compared to both
other groups, which is unsurprising due to the frequency of
bronchiectasis in post-infectious sequelae. The relatively
high proportion of hemoptysis in ALRIHL group may be due
to necrotizing bacteria, K. pneumoniae or B. pseudomallei,
which have previously been described by our team, or to
smear-negative TB. [6,7]. In Cambodia, smear-negative TB
accounted for 20% of the 38 555 TB cases notified in 2011
[14]. Due to limitations of Cambodian laboratory facilities,
TB culture is not available. Thus, in our study, smear-
negative TB cases would have been missed.
H. influenzae, S. pneumoniae and P. aeruginosa colonize
airways during the course of non-cystic fibrosis bronchiec-
tasis and chronic obstructive pulmonary diseases [15e17].
In the elderly, acute exacerbations of chronic obstructive
pulmonary disease, including bronchiectasis exacerbations,
are clearly associated with the presence of these bacteria
[18]. Our results are consistent with other studies con-
ducted in Thailand and in China, where P. aeruginosa and
Haemophilus influenza were also the two most frequent
pathogens in patients with steady-state bronchiectasis
[19,20]. Pseudomonas colonization of bronchiectasis is
associated with forced expired volume decline [20],
increased courses of oral antibiotics, increased hospital
admissions [21], and subsequent alteration of the quality of
life [22]. Unfortunately, spirometric measures are not
available in provincial Cambodian hospitals.
This study was not designed to document the epidemi-
ology of mycological and atypical mycobacteria. Fungi suchas Aspergillus spp. may also colonize bronchiectasis and pre-
existingcavities, enhancing hemoptysis when aspergilloma
erode bronchial arteries [23]. A short prevalence assessment
from the same prospective study performed in 2010 among
138 consecutive patients showed that 21 (15%) were infected
with non-tuberculous mycobacteria (i.e Mycobacterium
avium intracellulare, M. scrofulaceum, M. abscessus, M.
fortuitum, Mycobacterium spp.) in at least one of three
consecutive sputum samples (Institut Pasteur in Cambodia
unpublished data). Of these 21 patients, nine presentedwith
ALRIPS. It has been shown that patients with bronchiectasis
and post-TB sequelae have a higher risk than other chronic
respiratory diseases to develop non-tuberculous myco-
bacteriosis [24]. Nevertheless, the pathogenicity of atypical
mycobacteria is difficult to establish in this study and envi-
ronmental contaminations cannot be excluded [25]. Clini-
cians, however, have to be aware of such diseases that could
overestimate the TB burden. Developing mycobacteria cul-
ture and identification throughout the country could help to
address this issue.
The currently first-line empirical antibiotic used for ALRI
in Cambodia is penicillin A, which remained active on 74% of
Streptococcus pneumonia strains found in the ALRIPS group.
However, 42% of isolated H. influenzae and all P. aeruginosa
strains were resistant to this antibiotic. Cambodian antibi-
otics guidelines for ALRI are currently under revision and will
be adjusted to the local epidemiology. In theory, amoxicillin-
clavulanate, ceftriaxone or cefotaxime, or fluoroquinolones
are possible choices for first line therapy. There are, how-
ever, two major obstacles to the broad use of fluo-
roquinolones as first-line empirical treatment in Cambodia.
On one hand, ofloxacine and ciprofloxacine are not effective
as anti-pneumococcal drugs and 13% of P. aeruginosa were
resistant to ciprofloxacine in our study. On the other hand,
Superinfections of lung sequelae 1631fluoroquinolones currently remain active in TB. [26].
Generalization of fluoroquinolones use could therefore
delay TB diagnosis, and trigger widespread emergence of
resistant TB strains [27]. Since the presentation of the
ALRIPS patients was less severe on admission, fluo-
roquinolones could be proposed in this group only as a
second-line therapy if the first-line treatment is found to be
ineffective upon re-evaluation and after the results of AFB
screening.
Hospital stay was longer in the ALRIPS group contributing
to direct and indirect cost for patient’s family. In addition,
the low percentage of mortality in this study may be due to
under-reported deaths. Patients frequently died at home
just after discharge, as already shown in another Cambo-
dian publication about ALRI patients infected with K.
pneumonia and in a Vietnamese study in HIV-TB co-infected
patients [7,28].
One limitation of the study is that diagnosis was based
on only one chest radiograph performed on admission. The
SISEA project lacked funding to perform follow-up radio-
logical assessment. Most (86%) of the radiographs in our
ALRIPS group showed obvious sequelae, which could have
easily been recognized by clinicians. However, chest ra-
diographs have limited sensitivity to detect mild abnor-
malities, and especially bronchiectasis. Some cases with
mild bronchiectasis could have been classified in ALRIHL
group. In a Thai study on bronchiectasis, 10% of the patients
with bronchiectasis detected by computed tomography
(CT) scan had a normal chest radiograph [19]. CT scan
would have been a better diagnosis tool than chest radio-
graph in this case, but unfortunately it is not available in
Cambodian provincial hospitals.
Conclusion
In conclusion, clinical misdiagnosis and mismanagement of
superinfections on post-infectious pulmonary sequelae
are frequent and represent a serious threat to patients,
to public health and to healthcare finances in a TB-
hyperendemic country such as Cambodia. Improving the
detection of chronic bronchitis signs, training clinicians on
chest radiograph interpretation, implementing mycobac-
teria culture in Cambodian’s laboratories, and implement-
ing the use of simple spirometric measures could help this
diagnosis. Further studies are needed to assess the decline
of forced expiratory volume and the reduction of the long-
term functional prognosis and quality of life of Cambodian
patients, in addition to assess the generating added costs to
families and the Cambodian health system.
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